Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 4:10 PM ET
Monte Rosa Therapeutics Inc (GLUE) Statistics
Monte Rosa Therapeutics (GLUE) has a market cap of $800.67M and an enterprise value of $755.49M. It kept -186.24% of revenue as net income over the last 12 months. Its share count is up 23.54% from a year earlier.
Total Valuation
Enterprise value is 5.64% below the market cap, as cash exceeds debt.
| Market Cap | $800.67M |
|---|---|
| Enterprise Value | $755.49M |
| Latest price (Nov 17, 2026) | $9.07 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 13.1x and 1.9x. Its year-end P/S ranged from 5.9x to 36.8x from 2023 to 2025.
| P/S Ratio | 13.1x |
|---|---|
| Forward P/S | 7.8x |
| P/B Ratio | 1.9x |
Price Statistics
The stock is down 36.84% over 52 weeks and trades 18.29% below its 50-day average.
| Beta (1Y) | 0.93 |
|---|---|
| 52-Week Change | -36.84% |
| 1-Month Change | -14.92% |
| 3-Month Change | -42.49% |
| 6-Month Change | -48.41% |
| 5-Year Change | -54.12% |
| Total Return (1Y) | -36.84% |
| Total Return (3Y CAGR) | +39.37% |
| Total Return (5Y CAGR) | -15.65% |
| Return vs SPY (1Y) | -45.74% |
| Max Drawdown (1Y) | -64.16% |
| Max Drawdown (3Y) | -64.29% |
| Sharpe Ratio (1Y) | -0.54 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $11.10 |
| 200-Day Average | $16.63 |
| 52-Week Range | $8.95 to $25.77 |
| RSI (14 Days) | 30.9 |
| Average Volume (20 Days) | 1.32M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.32x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.32x |
|---|---|
| Quick Ratio | 10.32x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -26.39% over the last 12 months, against a 5-year average of -37.19%.
| Return on Equity (ROE) | -26.39% |
|---|---|
| Return on Assets (ROA) | -18.77% |
| ROE (5Y Average) | -37.19% |
| ROA (5Y Average) | -24.32% |
| ROIC (5Y Average) | -21.97% |
| Asset Turnover | 0.12x |
| Receivables Turnover | 11.21x |
Scores
GLUE has an Altman Z-Score of 2.00, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.00 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $70.33M over the last 12 months is down 61.26% from the 12 months before.
| Revenue | $70.33M |
|---|---|
| Revenue Growth (YoY) | -61.26% |
| Gross Profit | $70.33M |
| Operating Income | -$150.82M |
| Pretax Income | -$129.94M |
| Net Income | -$130.97M |
| Reported EPS (TTM) | -$1.40 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 71.12% of the $697.73M in total assets.
| Cash and Equivalents | $45.18M |
|---|---|
| Total Debt | $0 |
| Net Cash | $45.18M |
| Net Cash Per Share | $0.44 |
| Working Capital | $578.02M |
| Shareholder Equity | $496.21M |
| Book Value Per Share | $4.87 |
| Total Assets | $697.73M |
| Total Liabilities | $201.52M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $8.92M of capital spending, operating cash flow left -$174.39M of free cash flow.
| Operating Cash Flow | -$165.47M |
|---|---|
| Capital Expenditures | $8.92M |
| Free Cash Flow | -$174.39M |
| FCF Per Share | -$2.04 |
| Depreciation and Amortization | $8.18M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -214.46%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -214.46% |
| Pretax Margin | -184.77% |
| Net Margin | -186.24% |
| FCF Margin | -247.98% |
Growth
| Book Value Per Share Growth (2Y CAGR) | +6.27% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +6.27% |
Dividends and Yields
GLUE does not pay a dividend. Its free cash flow yield is -18.89%.
| FCF Yield | -18.89% |
|---|---|
| Buyback Yield | -2.59% |
| Shareholder Yield | -2.59% |
Peer Position
Against 6 similar companies, GLUE has the 5th highest P/S.
P/S RatioPeer median 35.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 13.1x vs 35.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -61.26% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -29.10% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -29.10% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GLUE
What is GLUE's market cap?
Monte Rosa Therapeutics has a market cap of $800.67M. Its enterprise value, which adds debt and subtracts cash, is $755.49M.
How many shares of GLUE are outstanding?
Monte Rosa Therapeutics has 101.79M shares outstanding. The count is up 23.54% from a year earlier.
Does GLUE pay a dividend?
No. Monte Rosa Therapeutics does not pay a dividend.
How much debt does GLUE have?
Monte Rosa Therapeutics has $0 of total debt and $45.18M of cash and equivalents, a net cash position of $45.18M.
GLUE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors